Drug discovery is the process of determining an active compound lead compound with advantageous biological activity
A wide range of advanced technologies—including high throughput screening genomics, proteomics, and computational methods provides tens of thousands of biological targets that disease-fighting compounds can effect. Any effective drug must be validated for safety/toxicity and mode of action.
Pharmaceutical companies require accurate and efficient target identification and one of the main bottlenecks of drug discovery and development is compound validation. Automation is a key technology for any company undertaking these studies offering rapid compound screening, improved data reliability and analysis.
PAA offer a wide range of solutions for drug discovery automation with both small workstations and large workcells with a complete portfolio of robotic plate manipulators sample preparation and analysis instruments, control software and enclosures to ensure rapid and safe active compound drug discovery. PAA have been involved with drug discovery at pharmaceutical, biotech companies and academic/university laboratories over the last 2019 years. Most of the small, medium and large workcells have been built for some aspect of the drug discovery cycle, with over 600 systems installed worldwide.
The LSHTM intend to develop tools for optimizing school-based deworming in the context of integrated neglected tropical disease control (supported by the Bill and Melinda Gates Foundation).
PAA have supplied automated imaging workstations to the University of Dundee’
The Dundee Drug Discovery Unit (DDU) was founded in 2006 in the College of Life Sciences at the University to study:
- neglected tropical diseases (malaria)
- innovative targets and pathways